chikungunya disease in individuals ≥ 18 years of age who are at increased risk of exposure to chikungunya virus.
Chikungunya disease is transmitted by the Aedesdengue and Zika viruses, which are transmitted by the same Aedes mosquito.
For more information, see Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations and the FDA approved prescribing information for the chikungunya vaccine.
(See also Overview of Immunization.)
Advisory Committee on Immunization Practices (ACIP) approved recommendations for use of the vaccine among certain people who travel abroad and for laboratory workers in the United States.
People aged > 65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure to mosquitoes (moderate exposure could include travelers who might have at least 2 cumulative weeks of exposure to mosquitoes in indoor or outdoor settings) OR
People staying in such an area for a cumulative period of 6 months or more
The are
Immunodeficiency or immunosuppression due to disease or medical therapy (eg, from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy, or patients with HIV infection who are severely immunocompromised).
History of severe allergic reaction (eg, anaphylaxis) to any component of the vaccine
are
Appropriate medical treatment and supervision must be available in the event anaphylaxis occurs.
The vaccine may cause severe or prolonged chikungunya-like adverse reactions.
Vaccine viremia occurs in the first week following administration of the vaccine. It is not known if the vaccine virus can be transmitted from a pregnant individual to the fetus or neonate and cause fetal or neonatal adverse reactions. However, vertical transmission of wild-type chikungunya virus to neonates from pregnant individuals with viremia at delivery is common and can cause severe, potentially fatal chikungunya disease in neonates.
The common adverse effects reported in clinical studies were
Injection site reaction and tenderness
Headache
Fatigue
Myalgia
Arthralgia
Fever
Nausea
More Information
The following English-language resources may be useful. Please note that THE MANUAL is not responsible for the content of these resources.
Advisory Committee on Immunization Practices (ACIP): ACIP Recommendations
U.S. Food and Drug Administration (FDA): Chikungunya Vaccine, Live approved prescribing information
